Egrifta (Tesamorelin) Mechanism of Action: Full Pathway Explained

HealthRX.com

Tesamorelin works by stimulating the pituitary to release GH

Print or save as PDF

See the public record for Tesamorelin

  • Drug / tesamorelin (Egrifta SV, Egrifta WR), a growth hormone-releasing factor analog
  • Molecular target / GRF (GHRH) receptors on pituitary somatotroph cells [1]
  • Downstream signal / the body's own GH, then IGF-1 and IGFBP-3 [1]
  • Approved use / excess abdominal fat in HIV-infected adults with lipodystrophy [1]
  • Dose / Egrifta SV 1.4 mg daily or Egrifta WR 1.28 mg daily, subcutaneous [1][2]
  • Half-life / 8 minutes (Egrifta SV) and 11 minutes (Egrifta WR) in healthy subjects [1][2]
  • Trial effect on visceral fat / -15.2% vs +5.0% at 26 weeks in 412 patients [3]
  • Not / growth hormone, and not indicated for weight loss [1]

What tesamorelin is, and what it is not

Tesamorelin acetate is a synthetic analog of human growth hormone-releasing factor, also called growth hormone-releasing hormone or GHRH. It is the 44-amino-acid human sequence plus a hexenoyl group on the N-terminal tyrosine, with a molecular weight of about 5135.9 Da as the free base. It is a peptide, not growth hormone [1].

Egrifta was first approved on November 10, 2010 [4]. The two current products are Egrifta SV, a 2 mg vial dosed at 1.4 mg once daily, and Egrifta WR, an 11.6 mg vial dosed at 1.28 mg once daily. Both are subcutaneous injections into the abdomen, and the Egrifta WR label states the two are not substitutable [1][2].

The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label states Egrifta is not indicated for weight loss management because its effect on weight is neutral, and that long-term cardiovascular safety has not been established [1][2].

Step one: binding the GRF receptor on the pituitary

In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency to the body's own GRF [1]. Those receptors sit on pituitary somatotroph cells, the cells that make growth hormone.

The label states the outcome directly: GRF acts on the pituitary somatotroph cells to stimulate synthesis and pulsatile release of endogenous growth hormone [1].

Step two: growth hormone, then IGF-1 and IGFBP-3

Growth hormone is both anabolic and lipolytic. It acts through specific receptors on chondrocytes, osteoblasts, myocytes, hepatocytes and adipocytes, producing a range of effects, some but not all of which are mediated by IGF-1 made in the liver and in peripheral tissues [1].

Tesamorelin raises IGF-1 and IGFBP-3 [1]. In the 412-patient trial, IGF-1 rose 81.0% on tesamorelin and fell 5.0% on placebo at 26 weeks [3]. In the pooled analysis of 806 patients it rose 108 ng/mL versus a fall of 7 ng/mL [5]. The label tells prescribers to monitor IGF-1 during treatment. Among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores (SDS) and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23% [1].

Other pituitary hormones did not shift in a clinically significant way. The label reports no clinically significant changes in TSH, LH, ACTH or prolactin during the trials [1].

What the trials show about where the fat is lost

The trials measured visceral adipose tissue, the fat around the abdominal organs, by CT. In the pooled analysis of the two phase 3 trials, visceral fat changed by -24 cm2 on tesamorelin versus +2 cm2 on placebo, a treatment effect of -15.4%, while abdominal subcutaneous fat changed by -2 versus +2 cm2 (P=0.08) [5]. In the 404-patient trial, limb and abdominal subcutaneous fat did not change [6].

After subcutaneous injection of the original 2 mg dose, absolute bioavailability in healthy adults was less than 4% and median peak concentration arrived at 0.15 hours. The mean elimination half-life was 8 minutes for the 1.4 mg Egrifta SV dose and 11 minutes for the 1.28 mg Egrifta WR dose [1][2]. Exposure was 34% higher in HIV-infected patients than in healthy subjects [1].

A pharmacist's take on why tesamorelin targets deep belly fat, not weight

The pharmacist argues that tesamorelin is a targeted tool for deep belly fat rather than a general weight loss drug. In their view it prompts the brain to release more growth hormone, which raises IGF-1 and breaks down visceral fat, while fat under the skin is not the focus. They say the waist may shrink more than the scale moves, so people often misread the results. They warn it may not suit people with active cancer, uncontrolled diabetes, or pregnancy, and stress that it is not a substitute for lifestyle change and needs medical supervision.

Who is speaking?

RxIndianPharmacist. Registered pharmacist, as self-described on the RxIndianPharmacist channel Background

Episode notes and full video

What the trials measured

Falutz 2007 (NEJM), the label's Study 1. 412 HIV-infected adults received tesamorelin 2 mg or placebo daily for 26 weeks. Visceral fat fell 15.2% versus a 5.0% rise; triglycerides fell 50 mg/dL versus a 9 mg/dL rise; the total-to-HDL cholesterol ratio fell 0.31 versus a 0.21 rise; IGF-1 rose 81.0% versus a 5.0% fall (P<0.001 for all) [3]. The label reports the same trial as least-squares means: -27 versus +4 cm2, a difference of -31 cm2 (95% CI -39 to -24) [1].

Falutz 2010 (JAIDS), the label's Study 2. 404 patients were randomized 2:1. At 6 months visceral fat fell 10.9% (-21 cm2) versus 0.6% (-1 cm2) on placebo (P<0.0001) [6]. Patients who continued tesamorelin through 12 months kept roughly an 18% reduction. Those switched to placebo regained fat: visceral fat from week 26 to 52 changed by 0% to -5% on continued treatment versus +16% to +22% on placebo [1][6].

Pooled phase 3 analysis (JCEM). 806 patients: visceral fat -24 versus +2 cm2, a treatment effect of -15.4%; triglycerides -37 versus +6 mg/dL; IGF-1 +108 versus -7 ng/mL [5].

Stanley 2014 (JAMA). 50 patients received tesamorelin 2 mg (n=28) or placebo (n=22) for 6 months. Visceral fat changed -34 versus +8 cm2, a treatment effect of -42 cm2 (95% CI -71 to -14) [7].

Where the pathway becomes a safety issue

The label describes tesamorelin as inducing release of endogenous growth hormone, a known growth factor, and contraindicates use in active malignancy. It says a pre-existing malignancy should be inactive and its treatment complete before starting, and that the drug should be discontinued if malignancy recurs [1].

On glucose, HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% of placebo patients by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [1]. Fluid retention can appear as edema, joint pain or carpal tunnel syndrome [1]. Hypersensitivity reactions occurred in 4% of treated patients and included itching, redness, flushing, hives and rash; the label says to advise patients to seek prompt medical attention and discontinue treatment if a reaction is suspected [1]. Injection-site reactions occurred in 25% versus 14% on placebo during the first 26 weeks [1].

Who the pathway cannot work in

The labels contraindicate Egrifta in disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or pituitary surgery, head irradiation or head trauma), in active malignancy, in known hypersensitivity to tesamorelin or the excipients, and in pregnancy [1][2]. In rats, tesamorelin acetate given during organogenesis produced hydrocephaly in offspring at roughly two to four times the human exposure based on AUC [1].

What is not established

The effects of prolonged IGF-1 elevation are unknown [1]. Long-term cardiovascular safety has not been established [1]. No formal human metabolism studies have been performed, and kinetics in renal or hepatic impairment, in children and in people over 65 are not established [1]. With the original 1 mg/vial product, anti-tesamorelin IgG antibodies appeared in 50% of patients at 26 weeks and 47% at 52 weeks, with neutralizing antibodies in about 10% at week 52; fat loss and IGF-1 response were similar with or without antibodies [1].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. On which cells are the GRF receptors that tesamorelin binds located?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Tesamorelin: GHRH receptor targets and downstream GH and IGF-1 effects

Tesamorelin binds and stimulates GRF receptors in vitro. GRF acts on pituitary somatotroph cells to drive growth hormone release, and GH then acts on liver, fat and bone cells, partly via IGF-1.

Tesamorelin (Egrifta). Enters by injection under the skin.

Pituitary gland
  1. Pituitary gland: somatotroph cells

    Target: human GRF (GHRH) receptor

    Tesamorelin binds and stimulates human GRF receptors in vitro with potency similar to endogenous GRF.

    Product label

    Source: Egrifta Sv prescribing information, section 12.1 Mechanism of Action, Jul 29, 2026

What receptor does tesamorelin act on?
It binds and stimulates human GRF receptors on pituitary somatotroph cells, with potency similar to the body's own GRF [1]. That drives synthesis and pulsatile release of the patient's own growth hormone, which then raises IGF-1 and IGFBP-3 [1].
Is tesamorelin the same as growth hormone?
No. It is a 44-amino-acid peptide with a hexenoyl group on its N-terminal tyrosine and a molecular weight of about 5135.9 Da, and it works upstream of growth hormone by stimulating the pituitary [1].
How long does tesamorelin stay in the body?
The mean elimination half-life was 8 minutes after a 1.4 mg Egrifta SV dose and 11 minutes after a 1.28 mg Egrifta WR dose in healthy subjects, with median peak concentrations at 0.15 hours [1][2].
Does tesamorelin change triglycerides?
In the 412-patient trial, triglycerides fell 50 mg/dL on tesamorelin and rose 9 mg/dL on placebo over 26 weeks [3]. In the pooled analysis of 806 patients the change was -37 versus +6 mg/dL [5].
How much does tesamorelin raise IGF-1?
IGF-1 rose 81.0% on tesamorelin and fell 5.0% on placebo in the 26-week trial [3]. Among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [1].
What happens to visceral fat when tesamorelin stops?
In the trials it came back. Patients switched to placebo after 26 weeks had a 16% to 22% rise in visceral fat from week 26 to 52, versus 0% to -5% in those who continued treatment [1].
Show all 8 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  2. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  3. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
  4. Drugs@FDA: FDA-Approved Drugs.
  5. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
  6. Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
  7. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9.
  8. RxIndianPharmacist | Med Info | US Pharmacy Tips. Tesamorelin for Belly Fat? Pharmacist Explains Visceral Fat Loss, MOA & Risks. Accessed 2026-11-10.
Evidence overview for Egrifta (Tesamorelin) Mechanism of Action: Full Pathway Explained